New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo.
Leuk Lymphoma
; 48(6): 1179-86, 2007 Jun.
Article
em En
| MEDLINE
| ID: mdl-17577782
ABSTRACT
Although the therapy of Hodgkin lymphoma and anaplastic large cell lymphoma has been considerably improved during the last decades, high therapeutic toxicity, relapses, secondary tumors, and primary treatment failure(s) occur. Both malignancies are well suited for CD30-targeted immunotherapy because of their strong CD30 expression. We constructed an immunotoxin composed of a single chain variable fragment of a CD30 antibody fused to the human pancreatic ribonuclease, showing CD30-specific binding and ribonucleolytic activity resistant to the inhibitor RNasin. This immunotoxin revealed CD30-specific anti-tumor activity in BALB/c mice that were challenged with CD30-positive or CD30-negative syngeneic tumor cells.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ribonuclease Pancreático
/
Imunotoxinas
/
Antígeno Ki-1
/
Citotoxinas
Tipo de estudo:
Evaluation_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article